Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors-Reference-Cited by-同舟云学术

Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors

Published:2014-12-18 Issue:26 Volume:124 Page:3924-3931
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Springuel Lorraine¹²,Hornakova Tekla¹²,Losdyck Elisabeth¹²,Lambert Fanny¹²,Leroy Emilie¹²,Constantinescu Stefan N.¹²,Flex Elisabetta³,Tartaglia Marco³,Knoops Laurent¹²⁴,Renauld Jean-Christophe¹²

Affiliation:

1. Ludwig Institute for Cancer Research, Brussels Branch, Belgium;

2. de Duve Institute, Université Catholique de Louvain, Brussels, Belgium;

3. Istituto Superiore di Sanità, Rome, Italy; and

4. Hematology Unit, Cliniques Universitaires Saint-Luc, Brussels, Belgium

Abstract

Key PointsCells transformed by activating JAK1 mutations become resistant to JAK inhibitor by acquiring activating mutations in JAK3 and vice versa. JAK1 and JAK3 mutants cooperatively activate STAT transcription factors.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/124/26/3924/1466037/3924.pdf

Reference52 articles.

1. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction.;Saharinen;J Biol Chem,2002

2. STAT transcription factors in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.;Dorritie;Leukemia,2014

3. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.;Baxter;Lancet,2005

4. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.;James;Nature,2005

5. A gain-of-function mutation of JAK2 in myeloproliferative disorders.;Kralovics;N Engl J Med,2005

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PIM1 is a potential therapeutic target for the leukemogenic effects mediated by JAK/STAT pathway mutations in T-ALL/LBL;npj Precision Oncology;2024-07-20

2. Janus Kinase 3 (JAK3): A Critical Conserved Node in Immunity Disrupted in Immune Cell Cancer and Immunodeficiency;International Journal of Molecular Sciences;2024-03-04

3. A Workflow Combining Machine Learning with Molecular Simulations Uncovers Potential Dual-Target Inhibitors against BTK and JAK3;Molecules;2023-10-17

4. JAK3 Y841 Autophosphorylation Is Critical for STAT5B Activation, Kinase Domain Stability and Dimer Formation;International Journal of Molecular Sciences;2023-07-25

5. JAKs and STATs from a Clinical Perspective: Loss-of-Function Mutations, Gain-of-Function Mutations, and Their Multidimensional Consequences;Journal of Clinical Immunology;2023-05-04